Improved biopsy efficiency with MR/ultrasound fusion-guided prostate biopsy
Mené sur 1 003 patients avec suspicion de cancer de la prostate (âge moyen : 62 ans ; niveau sérique moyen du PSA : 10 ng/ml), cet essai évalue, du point de vue du taux de détection de la maladie, l'efficacité d'une biopsie ciblée à l'aide de fusions d'images échographiques et d'IRM par rapport à une biopsie standard
With the current controversy regarding the overdiagnosis and overtreatment of screen-detected prostate cancer (PCa) (1), the urologic community has focused efforts on identifying tools to improve patient risk stratification. Magnetic resonance imaging (MRI) and MRI-targeted biopsy (MRITB) have emerged as promising solutions (2). MRI offers a reduction in overdiagnosis by providing improved prebiopsy risk stratification and decreasing the detection of low-risk PCa. Additionally, MRITB may reduce overtreatment by providing a more accurate assessment of cancer location, grade, and size. In the current study (3), the authors utilize outcomes from their previously published MRITB cohort (4) to better define the benefits of MRITB. They examine the biopsy efficiency of MRITB compared with standard 12-core transrectal ultrasound (TRUS)–guided biopsy, with each patient serving as his own control.
This series of 1003 men includes both …
Journal of the National Cancer Institute , éditorial en libre accès, 2016